Key facts
- This page summarizes Richard A. Baron's Form 4 filing for Immunome Inc. (IMNM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2023, 16:52.
Richard A. Baron - 08 Jun 2023 Form 4 Insider Report for Immunome Inc. (IMNM)
- Reporting relationship
- Director
- Issuer ticker
- IMNM
- Reported as of
- 08 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2023, 16:52:28 UTC
- Prior SEC filing
- 21 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Purnanand D. Sarma, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard A. Baron filed Form 4 for Immunome Inc. (IMNM) on 12 Jun 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMNM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,500
- Change %
- Price
- $0.000000
- Shares after
- 6,500
- Date
- 08 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,500
- Exercise price
- $4.84
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the options shall vest 25% every quarter after the grant date.